Fooling mother nature: Epigenetics and novel treatments for psychiatric disorders

CNS Spectrums

Volumn 15, Issue 6, 2010, Pages 358-365

  Stahl, Stephen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; CLOZAPINE; FOLIC ACID DERIVATIVE; HALOPERIDOL; HISTONE DEACETYLASE INHIBITOR; METHYLFOLATE; MOOD STABILIZER; OLANZAPINE; SULPIRIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; DRUG RESEARCH; EPIGENETICS; GENE ACTIVATION; GENE SILENCING; HUMAN; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RNA INTERFERENCE; SCHIZOPHRENIA; TREND STUDY;

EID: 77953579241     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900029229     Document Type: Article

References (57)

1. Waddington CH. The Strategy of the Genes. New York, NY: MacMillan; 1957.
2. Nestler EJ. Epigenetic mechanisms in psychiatry. Biol Psychiatry. 2009;65:189-90.
3. Stahl SM. Epigenetics and methylomics in psychiatry. J Clin Psychiatry. 2009;70:1204-1205.
4. Sweatt JD. Experience-dependent epigenetic modifications in the central nervous system. Biol Psychiatry. 2009;65:191-197.
5. Stahl SM. Methylated Spirits: Epigenetic Hypotheses of Psychiatric Disorders. CNS Spectr. 2010;15:220-230.
6. Roffman JL, Gollub RL, Calhoun VD, et al. MTHFR 677C to T genotype disrupts prefrontal function in schizophrenia through an interactions with COMT 158 val to met. Proc Natl Acad Sci. 2008;105:17573-17578.
7. Roffman JL, Weiss AP, Decersbach T, et al. Interactive effects of COMT val108/158Met and MTHFR C677T on executive function in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:990-995.
8. Stahl SM. Stahls Essential Psychopharmacology, 3rd edition. New York, NY: Cambridge University Press; 2008.
9. Abdolmaleky HM, Cheng KH, Faraone SV, et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet. 2006;15:3132-3145.
10. Abdolmaleky HM, Smith CL, Zhou RJ, Thiagalingam S. Epigenetic alterations of dopaminergic system in major psychiatric disorders. In: Yan Q, ed. Pharmacogenomics in Drug Discovery and Development. New York, NY: Humana Press, 2008
11. Roffman JL, Weiss AP, Deckersbach T, et al. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. Schiz Res. 2007;92:181-188.
12. Roffman JL, Weiss AP, Purcell S, et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry. 2008;63:42-48.
13. Muntjewerff J-W, Gellekink H, den Heijer M, et al. Polymorphisms in catechol-O-methyltransferase and methylenetetrahydrofolate reductase in relation to the risk of schizophrenia. Eur Neuropsychopharmacol. 2008;18:99-106.
14. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta analysis. Mol Psychiatry. 2006;11:143-149.
15. Lewis SJ, Zammit S, Gunnell D, Smith, GD. A meta analysis of the MTHFR C677T polymorphism and schizophrenia risk. Am J Med Genet B Neuropsychiatr Genet. 2005;135B:2-4.
16. Arinami T, Yamada N, Yamakawa-Kobayashi K, Hamaguchi H, Toru M. Methylenetetrahydrofolate reductase variant and schizophrenia/depression. Am J Med Genet B Neuropsychiatr Genet. 1997;74:526-528.
17. Abdolmaleky HM, Smith CL, Farone SV, et al. Methylomics in psychiatry: modulation of gene-environment interactions may be through DNA methylation. Am J Med Genet B Neuropsychiatr Genet. 2004;127B:51-59.
18. Monteggia LM, Kavalali ET. Rett syndrome and the impact of MeCP2 associated transcriptional mechanisms on neurotransmission. Biol Psychiatry. 2009;65:204-210.
19. Akbarian S, Huang H-S. Epigenetic regulation in human brain: focus on histone lysine methylation. Biol Psychiatry. 2009;65:198-203.
20. Veldic M, Caruncho JH, Liu WS, et al. DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons on schizophrenia brains. Proc Nat Acad Sci. 2004;101:348-353.
21. Costa E, Dong E, Grayson DR, Guidotti A, Ruzicka W, Veldic. Reviewing the role of DNA (Cytosine-5) methyltransferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability. Epigenetics. 2007;2:29-36.
22. Veldic M, Kadriu B, Maloku E, et al. Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr Res. 2007;91:51-61.
23. Tremolizzo L, Caraboni G, Ruzicka WB, et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci. 2002;99:17095-17100.
24. Abdolmaleky HM, Cheng KH, Russo A, et al. Hypermethylation of the Reelin RELN promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet. 2005:134:60-66.
25. Abdolmaleky HM, Smith CL, Zhou J-R, Thiagalingam S. Epigenetic modulation of reelin function in schizophrenia and bipolar disorder. In: Fatem SH, ed. Reelin Glycoprotein: Structure, Biology and Roles in Health and Disease. New York, NY: Springer; 2008.
26. Noh JS, Sharma RP, Veldic M, et al. DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures. Proc Natl Acad Sci. 2005;102:1749-1754.
27. Grayson DR, Jia X, Chen Y, et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci. 2005;102:9341-9346.
28. Mill J, Tang T, Kaminsky Z, et al. Epigenomic profiling reveals DNA methylation changes associated with major psychosis. Am J Hum Genet. 2008;82:696-711.
29. Murphy BC, O'Reilly RL, Singh SM. Site specific cytosine methylation in S-COMT promoter in 31 brain regions with implications for studies involving schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2005;133:37-42.
30. Tochigi M, IwamotoK, Bundo M, et al. Methylation status of the reelin promoter region in the brain of schizophrenic patients. Biol Psychiatry. 2008;63:530-533.
31. Shimabukuro M, Sasaki T, Imamura A, et al. Global hypomethylation of peripheral leukocyte DNA in male patients with schizophrenia: a potential link between epigenetics and schizophrenia. J Psychiatr Res. 2007;41:1042-1046.
32. Connor CM, Akbarian S. DNA methylation changes in schizophrenia and bipolar disorder. Epigenetics. 2008;3:55-58.
33. Stahl SM. Novel Therapeutics for Depression: L-methylfolate (6 (S)-5 methyltetrahydrofolate (MTHF) as a Trimonoamine Modulator and Antidepressant Augmenting Agent. CNS Spectr. 2007;12:423-428.
34. Freeman JM, Finkelstein JM, Mudd SH. Folate-responsive homocysteinuria and "schizophrenia." A defect in methylation due to deficient 5,10-methylenetetrahydrofolate reductase activity. N Eng J Med. 1975;292:491-496.
35. Regland B, Johansson BV, Gottfries CG. Homocysteinemia and schizophrenia as a case of methylation deficiency. J Neural Transm Gen Sect. 1994;98:143-152.
36. Fiso S, Choi S-W, Girelli D, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci. 2002;99:5606-5611.
37. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: A HuGE Review. Am J Epidemiol. 2007;165:1-13.
38. Goff DC, Bottiglieri T, Arning E, et al. Folate, homocysteine and negative symptoms of schizophrenia. Am J Psychiatry. 2004;161:1705-1708.
39. Godfrey PSA, Toone BK, Carney MWB, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336:392-395.
40. Levine J, Stahl Z, Sela B-A, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry. 2006;60:265-269.
41. Kempisty B, Skiora J, Lianeri M, et al. MTHFD 1958G>A and MTR 2756A>G polymorphisms are associated with bipolar disorder and schizophrenia. Psychiatr Genet. 2007;17:177-181.
42. Zhao R, Chen Y, Tan W, et al. Relationship between dopamine-stimulated phospholipid methylation and the single-carbon folate pathway. J Neurochem. 2001;78:788-796.
43. Sharma A, Kramer ML, Wick PF, et al. D4 dopamine receptor-mediated phospholipid methylation and its implications for mental illnesses such as schizophrenia. Mol Psychiatry. 1999;4:235-246.
44. Nagothu KK, Rishi AK, Jaszewski R, Kocuk O, Majumdar AP. Folic acid-mediated inhibition of serum-induced activation of EGFR promoter in colon cancer cells. Am J Physiol Gastrointest Liver Physiol. 2004;287:G541-G546.
45. Cohen SM, Nichols A, Wyatt R, Pollin W. The administration of methionine to chronic schizophrenia patients: a review of 10 studies. Biol Psychiatry. 1974;8:209-225.
46. Strous RD, Ritsner MS, Adler S, et al. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAMe) augmentation in schizophrenia. Eur Neuropsychopharmacol. 2009;19:14-22.
47. Ingrosso D, Cimmino A, Perna AF, et al. Folate treatment and unbalanced methylation and changes in allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet. 2003;361:1693-1699.
48. Lamers Y, Prinz-Langenohl R, Bramswig S, Pietrzik K. Red blood cell folate concentrations increase more after supplementation with (6S)-5-methyltetrahydrofolate than with folic acid in women of childbearing age. Am J Clin Nutr. 2006;84:156-161.
49. Krauss-Etschmann S, Shadid R, Campoy C, et al. Effects of fish oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial. Am J Clin Nutr. 2007;85:1392-1400.
50. Houghton LA, Sherwood KL, Pawlosky R, Ito S, O'Connor DL. (6S)-5-methytetrahydrofolate is at least as effective as folic acid in preventing a decline in blood folate concentrations during lactation. Am J Clin Nutr. 2006;83:842-850.
51. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer and teratogen. J Biol Chem. 2001;276:36734-36741.
52. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia. 2004;45:737-744.
53. Chuang D-M, Leng Y, Marinova Z, Kim H-Y, Chiu C-T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009;32:591-601.
54. Guidotti A, Dong E, Kundakovic M, Satta R, Grayson DR, Costa E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacolog Sci. 2008;30:55-60.
55. Perisic T, Zimmermann, N, Kirmeier T, et al., Valproate and amitriptyline exert common and divergent influences on global and gene promoter-specific chromatin modifications in rat primary astrocytes. Neuropsychopharmacol. 2010;35:792-805.
56. Dong E, Nelson M, Grayson DR, Costa E, Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA methylation. Proc Natl Acad Sci. 2008;105:13614-13619.
57. Martinez MA. RNA Interference and Viruses. New York, NY and Madrid, Spain: Caister Academic Press; 2010.